EMEA completes the review of recombinant factor VIII products and inhibitor development

View source ↗

Summary

EMA completes review of recombinant factor VIII products and inhibitor development, focusing on safety and immunogenicity concerns related to inhibitors in pati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia